Factor VIII products and inhibitor development in severe hemophilia A

Samantha C. Gouw, Johanna G. Van Der Bom, Rolf Ljung, Carmen Escuriola, Ana R. Cid, Ségolène Claeyssens-Donadel, Christel Van Geet, Gili Kenet, Anne Mäkipernaa, Angelo Claudio Molinari, Wolfgang Muntean, Rainer Kobelt, George Rivard, Elena Santagostino, Angela Thomas, H. Marijke Van Den Berg

Research output: Contribution to journalArticle

Abstract

BACKGROUND: For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development). METHODS: We evaluated 574 consecutive patients with severe hemophilia A (factor VIII activity,

Original languageEnglish
Pages (from-to)231-239
Number of pages9
JournalNew England Journal of Medicine
Volume368
Issue number3
DOIs
Publication statusPublished - Jan 17 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Factor VIII products and inhibitor development in severe hemophilia A'. Together they form a unique fingerprint.

  • Cite this

    Gouw, S. C., Van Der Bom, J. G., Ljung, R., Escuriola, C., Cid, A. R., Claeyssens-Donadel, S., Van Geet, C., Kenet, G., Mäkipernaa, A., Molinari, A. C., Muntean, W., Kobelt, R., Rivard, G., Santagostino, E., Thomas, A., & Van Den Berg, H. M. (2013). Factor VIII products and inhibitor development in severe hemophilia A. New England Journal of Medicine, 368(3), 231-239. https://doi.org/10.1056/NEJMoa1208024